* Adverum Biotechnologies Inc ADVM.OQ reported a quarterly
adjusted loss of $1.50 per share for the quarter ended in
March, higher than the same quarter last year, when the company
reported EPS of $-2.90. The mean expectation of seven analysts
for the quarter was for a loss of $1.40 per share. Wall Street
expected results to range from $-1.91 to $-1.20 per share.
* Reported revenue was zero; analysts expected $85.00
thousand.
* Adverum Biotechnologies Inc's reported EPS for the quarter
was a
loss of $1.50.
* The company reported a quarterly loss of $24.79 million.
* Adverum Biotechnologies Inc shares had fallen by 30.6%
this
quarter and gained 30.3% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 48.3%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Adverum
Biotechnologies Inc is $35.00
This summary was machine generated from LSEG data May 9 at 10:29
p.m. UTC. All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -1.40 -1.50 Missed
Dec. 31 2023 -3.37 -2.30 Beat
Sep. 30 2023 -3.15 -3.30 Missed
Jun. 30 2023 -3.29 -3.10 Beat